573 related articles for article (PubMed ID: 22040680)
1. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
2. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
3. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
4. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U
J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
6. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
7. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
8. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
9. A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.
Ramis I; Otal R; Carreño C; Domènech A; Eichhorn P; Orellana A; Maldonado M; De Alba J; Prats N; Fernández JC; Vidal B; Miralpeix M
Pharmacol Res; 2015 Sep; 99():116-24. PubMed ID: 26051661
[TBL] [Abstract][Full Text] [Related]
10. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
12. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
Moy LY; Jia Y; Caniga M; Lieber G; Gil M; Fernandez X; Sirkowski E; Miller R; Alexander JP; Lee HH; Shin JD; Ellis JM; Chen H; Wilhelm A; Yu H; Vincent S; Chapman RW; Kelly N; Hickey E; Abraham WM; Northrup A; Miller T; Houshyar H; Crackower MA
Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1085-92. PubMed ID: 23889698
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.
van Bree SH; Gomez-Pinilla PJ; van de Bovenkamp FS; Di Giovangiulio M; Farro G; Nemethova A; Cailotto C; de Jonge WJ; Lee K; Ramirez-Molina C; Lugo D; Skynner MJ; Boeckxstaens GE; Matteoli G
Gut; 2013 Nov; 62(11):1581-90. PubMed ID: 23242119
[TBL] [Abstract][Full Text] [Related]
16. Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
Rossi AB; Herlaar E; Braselmann S; Huynh S; Taylor V; Frances R; Issakani SD; Argade A; Singh R; Payan DG; Masuda ES
J Allergy Clin Immunol; 2006 Sep; 118(3):749-55. PubMed ID: 16950297
[TBL] [Abstract][Full Text] [Related]
17. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
19. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
20. Critical role for Syk in responses to vascular injury.
Andre P; Morooka T; Sim D; Abe K; Lowell C; Nanda N; Delaney S; Siu G; Yan Y; Hollenbach S; Pandey A; Gao H; Wang Y; Nakajima K; Parikh SA; Shi C; Phillips D; Owen W; Sinha U; Simon DI
Blood; 2011 Nov; 118(18):5000-10. PubMed ID: 21881044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
